Transplant Surgery — MCQs

Q: After the first postoperative year of cardiac transplantation, what is the most common cause of death?

Accelerated graft arteriosclerosis. **Explanation:** The survival of cardiac transplant recipients is divided into two distinct phases: the early postoperative period (within the first year) and the late postoperative period (after one year). **Why 'Accelerated Graft Arteriosclerosis' is correct:** Also known as **Cardiac Allograft Vasculopathy (CAV)**, this is a unique, progressive form of chronic rejection. Unlike typical atherosclerosis, CAV is characterized by diffuse, concentric intimal proliferation affecting the entire length of the coronary arteries. It remains the leading cause of late mortality (after 1 year) because the denervated heart does not experience typical angina, often leading to silent myocardial infarction, heart failure, or sudden death. **Why the other options are incorrect:** * **Infection:** This is the **most common cause of death within the first year** (specifically the first 30 days to 6 months) due to intense induction immunosuppression. * **Acute Rejection:** This typically occurs within the first 3–6 months. While it remains a risk, its incidence decreases significantly after the first year due to maintenance therapy. * **Arrhythmia:** While arrhythmias can occur due to surgical trauma or acute rejection in the early phase, they are rarely the primary cause of late-term mortality unless secondary to CAV. **High-Yield Clinical Pearls for NEET-PG:** 1. **Most common cause of death ( 1 year):** Cardiac Allograft Vasculopathy (CAV) / Graft Arteriosclerosis. 3. **Gold Standard for CAV diagnosis:** Annual coronary angiography with **Intravascular Ultrasound (IVUS)**, as angiography alone may underestimate the diffuse narrowing. 4. **Malignancy:** The risk of lymphomas (PTLD) and skin cancers increases significantly in the late phase due to long-term immunosuppression.

Q: Which of the following should be avoided in the long-term follow-up of a renal transplant recipient on ciclosporin?

All of the above. In renal transplant recipients on long-term immunosuppression with Ciclosporin, management focuses on preventing graft rejection, avoiding nephrotoxicity, and managing drug-drug interactions. **Explanation of Options:** * **A. Live Vaccines:** Immunosuppressed patients (on Ciclosporin, Tacrolimus, or Mycophenolate) have a diminished immune response. Administering live-attenuated vaccines (e.g., BCG, MMR, Yellow Fever) carries a significant risk of causing disseminated infection from the vaccine strain itself. * **B. Cytochrome P450 (CYP3A4) Inhibitors:** Ciclosporin is extensively metabolized by the hepatic CYP3A4 enzyme system. Drugs that inhibit this system (e.g., Erythromycin, Ketoconazole, Diltiazem) decrease Ciclosporin metabolism, leading to toxic blood levels. Conversely, CYP inducers (e.g., Rifampicin, Phenytoin) lower levels, risking graft rejection. * **C. NSAIDs:** Ciclosporin causes vasoconstriction of the afferent arterioles, reducing renal blood flow. NSAIDs inhibit prostaglandins, which are necessary to maintain afferent arteriolar vasodilation. Combining the two leads to synergistic pre-renal vasoconstriction and acute-on-chronic nephrotoxicity. **Clinical Pearls for NEET-PG:** * **Gingival Hyperplasia:** A classic side effect of Ciclosporin (also seen with Phenytoin and Nifedipine). * **Monitoring:** Therapeutic Drug Monitoring (TDM) is essential for Ciclosporin due to its narrow therapeutic index. * **Metabolic Profile:** Ciclosporin is associated with "H" side effects: **H**ypertension, **H**yperlipidemia, **H**yperglycemia, **H**irsutism, and **H**yperkalemia. * **Tacrolimus vs. Ciclosporin:** Tacrolimus is more potent and lacks hirsutism/gingival hyperplasia but has a higher incidence of New-Onset Diabetes After Transplantation (NODAT).

Q: What type of graft is a graft from a sister to a brother?

Allograft. ### Explanation The correct answer is **Allograft (Option B)**. **1. Why Allograft is correct:** An **allograft** (or homograft) is a transplant between two genetically non-identical members of the same species. Since a brother and sister share approximately 50% of their genetic material (unless they are monozygotic twins), they are genetically distinct individuals. Therefore, any organ or tissue transfer between them is classified as an allograft. This requires immunosuppression to prevent T-cell mediated rejection. **2. Why other options are incorrect:** * **Isograft (Option A):** This is a graft between genetically identical individuals. In humans, this only occurs between **monozygotic (identical) twins**. Since the question specifies a brother and sister (who are dizygotic/siblings), they cannot be genetically identical. * **Autograft (Option C):** This involves a graft taken from one part of a patient's body and transferred to another part of the **same individual** (e.g., a skin graft from the thigh to the arm or a CABG using the radial artery). There is no risk of rejection. * **Heterograft (Option D):** Also known as a **Xenograft**, this is a transplant between members of **different species** (e.g., a porcine/pig heart valve transplanted into a human). **3. Clinical Pearls for NEET-PG:** * **Hyperacute Rejection:** Occurs within minutes to hours due to pre-formed antibodies (Type II Hypersensitivity). * **Acute Rejection:** Occurs within days to weeks; primarily T-cell mediated (Type IV Hypersensitivity). * **Chronic Rejection:** Occurs months to years later; characterized by fibrosis and vascular occlusion. * **Order of Immunogenicity:** Xenograft > Allograft > Isograft = Autograft. * **Graft-versus-Host Disease (GVHD):** Most common in bone marrow transplants where donor T-cells attack the recipient's tissues.

Q: A parathyroid gland is implanted into the forearm muscle. What type of transplantation is this?

Heterotopic. ### Explanation The correct answer is **Heterotopic** transplantation. **1. Why Heterotopic is Correct:** In transplant surgery, the classification is based on the anatomical site of implantation. **Heterotopic transplantation** occurs when a tissue or organ is implanted into an anatomical location different from its original physiological position. * **Clinical Context:** In patients undergoing total parathyroidectomy (e.g., for secondary hyperparathyroidism), a portion of the parathyroid gland is often autotransplanted into the **brachioradialis muscle** of the forearm. This allows the gland to maintain endocrine function while being easily accessible for monitoring or partial resection if recurrence occurs. **2. Why Other Options are Incorrect:** * **Orthotopic (Option A):** This refers to placing the graft in its **normal anatomical position** after removing the diseased organ. A classic example is a Liver Transplant, where the donor liver replaces the recipient's liver in the right upper quadrant. * **Auxiliary (Option C):** This is a subtype of heterotopic transplant where the graft is placed in a different location **without removing the recipient's native organ**. The graft "assists" the failing organ. An example is an auxiliary liver transplant placed in the infra-mesocolic space. **3. High-Yield Clinical Pearls for NEET-PG:** * **Autograft:** Transfer of tissue within the same individual (e.g., the parathyroid forearm transplant mentioned above). * **Allograft:** Transfer between genetically different members of the same species (most cadaveric organ transplants). * **Isograft (Syngeneic):** Transfer between genetically identical individuals (monozygotic twins). * **Xenograft:** Transfer between different species (e.g., porcine heart valve). * **Renal Transplant:** Most kidney transplants are **Heterotopic** (placed in the iliac fossa), not orthotopic.

Q: Which of the following is not a component of the University of Wisconsin solution?

Potassium citrate. The **University of Wisconsin (UW) solution** is the "gold standard" for cold storage of intra-abdominal organs (liver, pancreas, and kidney). Its primary goal is to minimize cell swelling and prevent oxidative damage during ischemia. ### Why Potassium Citrate is the Correct Answer The UW solution is an **intracellular-type** solution, meaning it contains high concentrations of potassium and low concentrations of sodium to mimic the intracellular environment. However, the potassium source in UW solution is **Potassium Lactobionate**, not Potassium citrate. Potassium citrate is typically used in cardioplegic solutions (like St. Thomas solution) to induce cardiac arrest, but it is not a component of the UW formula. ### Explanation of Incorrect Options * **Adenosine (Option A):** Included as a precursor for ATP synthesis, helping the organ regain energy stores once reperfused. * **Glutathione (Option B):** Acts as a potent antioxidant to reduce oxidative stress and neutralize free radicals during the reperfusion phase. * **Allopurinol (Option C):** A xanthine oxidase inhibitor that prevents the formation of reactive oxygen species (ROS), protecting the graft from reperfusion injury. ### High-Yield Clinical Pearls for NEET-PG * **Key Components of UW Solution:** Lactobionate and Raffinose (prevent osmotic swelling), Hydroxyethyl starch (HES - prevents interstitial edema), and Magnesium sulfate. * **Mechanism:** It works by preventing the "sodium-potassium pump" failure that occurs during cold ischemia. * **Storage Time:** It allows for liver preservation for up to 12–18 hours and kidney preservation for up to 48–72 hours. * **Note:** Because of its high potassium content (120 mEq/L), the solution must be thoroughly flushed out of the organ before anastomosis to prevent **systemic hyperkalemia** and cardiac arrest in the recipient.

Q: Which immunosuppressive drug is commonly given after renal transplantation?

Corticosteroids. **Explanation:** In renal transplantation, the primary goal of immunosuppression is to prevent graft rejection while minimizing systemic toxicity. **Corticosteroids** (such as Prednisolone) are a cornerstone of post-transplant maintenance therapy. They act by inhibiting the expression of multiple inflammatory cytokines (like IL-1, IL-2, and TNF-alpha) and suppressing T-cell activation. Most transplant protocols utilize a "triple drug regimen" consisting of a Calcineurin Inhibitor (e.g., Tacrolimus), an Antiproliferative agent (e.g., Mycophenolate Mofetil), and **Corticosteroids**. **Analysis of Options:** * **A. Cyclophosphamide:** While an immunosuppressant, it is primarily used in chemotherapy or for specific autoimmune conditions (like Wegener’s granulomatosis). It is rarely used in routine transplant maintenance due to its significant toxicity profile (e.g., hemorrhagic cystitis). * **C. Interferon:** This is an immunomodulator, not an immunosuppressant. In fact, interferons *stimulate* the immune system to fight viruses or tumors and could potentially trigger graft rejection if administered post-transplant. * **D. All of the above:** Incorrect, as only corticosteroids are standard post-transplant therapy among the choices. **High-Yield Clinical Pearls for NEET-PG:** * **Standard Triple Therapy:** Tacrolimus + Mycophenolate Mofetil (MMF) + Prednisolone. * **Drug of Choice for Induction:** Basiliximab (IL-2 receptor antagonist) or Antithymocyte Globulin (ATG). * **Side Effects of Steroids:** Hyperglycemia (Post-Transplant Diabetes Mellitus), osteoporosis, peptic ulcers, and impaired wound healing. * **Tacrolimus vs. Cyclosporine:** Tacrolimus is generally preferred due to a lower incidence of rejection and fewer cosmetic side effects (like gingival hyperplasia or hirsutism).

Q: What is the common site for islet cell transplantation in patients with diabetes mellitus?

Injected into the portal vein. **Explanation:** The correct answer is **D. Injected into the portal vein.** In islet cell transplantation, the goal is to deliver insulin-producing beta cells into a highly vascularized environment that allows for rapid engraftment and glucose sensing. The **portal vein** is the preferred site because it allows the islets to lodge in the **liver sinusoids**. This site is physiologically advantageous as it mimics the natural portal circulation, where insulin is secreted directly into the liver—the primary organ for glucose metabolism. The procedure is typically performed via percutaneous transhepatic catheterization under radiologic guidance. **Why other options are incorrect:** * **A. Forearm muscles:** While the forearm is a common site for **parathyroid autotransplantation**, it lacks the specific microenvironment and portal-venous drainage required for optimal islet cell function and metabolic regulation. * **B. Pelvis:** This is the standard anatomical site for **whole-organ kidney or pancreas transplantation** (specifically the iliac fossa), but it is not used for cellular islet infusion. * **C. Thigh:** Similar to the forearm, the intramuscular environment of the thigh does not provide the necessary vascular architecture or physiological feedback loops for islet survival. **Clinical Pearls for NEET-PG:** * **The Edmonton Protocol:** The landmark protocol for islet transplantation involving corticosteroid-free immunosuppression. * **Source:** Islets are isolated from a cadaveric donor pancreas using **Collagenase** digestion. * **Complications:** The most common immediate complication of portal vein infusion is **portal vein thrombosis** or transient elevation of liver enzymes. * **Success Metric:** The primary goal is achieving "insulin independence," though many patients eventually require supplemental insulin over time.

Q: What is the most common indication for heart transplant?

Dilated cardiomyopathy. **Explanation:** **Correct Answer: A. Dilated cardiomyopathy** Heart transplantation is the definitive treatment for end-stage heart failure that is refractory to medical management. Globally, the most common indication for heart transplantation in adults is **Dilated Cardiomyopathy (DCM)**, followed closely by Ischemic Cardiomyopathy. DCM leads to progressive ventricular enlargement and systolic dysfunction, eventually reaching a point where the heart can no longer maintain adequate cardiac output. **Analysis of Incorrect Options:** * **B. Myocardial Infarction (MI):** While acute MI is a leading cause of death, it is managed with reperfusion (PCI/CABG). It only leads to transplant if it results in chronic, end-stage **Ischemic Cardiomyopathy**. * **C. Hypertrophic cardiomyopathy (HCM):** Although HCM can lead to heart failure or sudden cardiac death, it is a much less frequent indication for transplant compared to the high prevalence of DCM. * **D. Tetralogy of Fallot (TOF):** This is a congenital cyanotic heart disease usually managed with surgical repair (Blalock-Taussig shunt or total correction) in infancy/childhood. Congenital heart diseases are the most common indication in the **pediatric** age group, but not the overall population. **High-Yield Clinical Pearls for NEET-PG:** * **Most common indication (Adults):** Dilated Cardiomyopathy. * **Most common indication (Pediatrics):** Congenital Heart Disease. * **Gold Standard for Diagnosis of Rejection:** Endomyocardial biopsy (usually taken from the right ventricle). * **Denervated Heart:** A transplanted heart lacks autonomic nerve supply; therefore, it does not respond to Atropine, and patients do not experience classic angina (silent ischemia). * **Most common cause of late death:** Cardiac Allograft Vasculopathy (CAV).

Transplant Surgery Indian Medical PG Practice Questions and MCQs

Question 1: After the first postoperative year of cardiac transplantation, what is the most common cause of death?

A. Infection
B. Arrhythmia
C. Accelerated graft arteriosclerosis (Correct Answer)
D. Acute rejection episode

Explanation: **Explanation:** The survival of cardiac transplant recipients is divided into two distinct phases: the early postoperative period (within the first year) and the late postoperative period (after one year). **Why 'Accelerated Graft Arteriosclerosis' is correct:** Also known as **Cardiac Allograft Vasculopathy (CAV)**, this is a unique, progressive form of chronic rejection. Unlike typical atherosclerosis, CAV is characterized by diffuse, concentric intimal proliferation affecting the entire length of the coronary arteries. It remains the leading cause of late mortality (after 1 year) because the denervated heart does not experience typical angina, often leading to silent myocardial infarction, heart failure, or sudden death. **Why the other options are incorrect:** * **Infection:** This is the **most common cause of death within the first year** (specifically the first 30 days to 6 months) due to intense induction immunosuppression. * **Acute Rejection:** This typically occurs within the first 3–6 months. While it remains a risk, its incidence decreases significantly after the first year due to maintenance therapy. * **Arrhythmia:** While arrhythmias can occur due to surgical trauma or acute rejection in the early phase, they are rarely the primary cause of late-term mortality unless secondary to CAV. **High-Yield Clinical Pearls for NEET-PG:** 1. **Most common cause of death (<1 year):** Infection. 2. **Most common cause of death (>1 year):** Cardiac Allograft Vasculopathy (CAV) / Graft Arteriosclerosis. 3. **Gold Standard for CAV diagnosis:** Annual coronary angiography with **Intravascular Ultrasound (IVUS)**, as angiography alone may underestimate the diffuse narrowing. 4. **Malignancy:** The risk of lymphomas (PTLD) and skin cancers increases significantly in the late phase due to long-term immunosuppression.

Question 2: Infection in a renal transplant patient is usually caused by which pathogen?

A. Cytomegalovirus (CMV) (Correct Answer)
B. Human Immunodeficiency Virus (HIV)
C. Herpes Simplex Virus (HSV)
D. Salmonella

Explanation: **Explanation:** **Cytomegalovirus (CMV)** is the most common clinically significant opportunistic viral pathogen in renal transplant recipients. It typically manifests between **1 to 6 months post-transplant**, coinciding with the period of maximal immunosuppression. The infection occurs due to primary infection (seronegative recipient receiving a seropositive organ), reactivation of latent virus, or superinfection. CMV is high-yield because it not only causes systemic symptoms (fever, leukopenia) and organ-specific disease (pneumonitis, hepatitis, colitis) but also acts as an immunomodulator, increasing the risk of graft rejection and other opportunistic infections. **Analysis of Incorrect Options:** * **HIV (Option B):** While HIV is a significant viral pathogen, it is not a common "post-transplant infection." In fact, HIV-positive status was previously a contraindication to transplant, though "HIV-to-HIV" transplants are now performed in specific protocols. * **HSV (Option C):** Herpes Simplex Virus can cause mucocutaneous lesions in the early post-operative period, but its incidence has significantly decreased due to routine prophylactic use of Acyclovir/Valacyclovir. It is less common and less severe than CMV. * **Salmonella (Option D):** While transplant patients are at higher risk for intracellular bacterial infections like Salmonella, it is far less frequent than viral pathogens like CMV. **High-Yield Clinical Pearls for NEET-PG:** * **Timeline of Infection:** * *<1 month:* Bacterial infections (UTI, wound infection) and donor-derived infections. * *1–6 months:* **CMV (Peak incidence)**, BK virus, and opportunistic infections (PJP). * *6+ months:* Community-acquired pneumonia or chronic viral infections (HCV, HBV). * **Diagnosis:** Quantitative PCR for CMV DNA is the gold standard. * **Treatment:** Intravenous **Ganciclovir** or oral Valganciclovir. * **Prophylaxis:** Most centers use Valganciclovir for 3–6 months post-transplant to prevent CMV.

Question 3: Which of the following should be avoided in the long-term follow-up of a renal transplant recipient on ciclosporin?

A. Administer live vaccines
B. Prescribe drugs that inhibit cytochrome P450 activity
C. Prescribe NSAIDs
D. All of the above (Correct Answer)

Explanation: In renal transplant recipients on long-term immunosuppression with Ciclosporin, management focuses on preventing graft rejection, avoiding nephrotoxicity, and managing drug-drug interactions. **Explanation of Options:** * **A. Live Vaccines:** Immunosuppressed patients (on Ciclosporin, Tacrolimus, or Mycophenolate) have a diminished immune response. Administering live-attenuated vaccines (e.g., BCG, MMR, Yellow Fever) carries a significant risk of causing disseminated infection from the vaccine strain itself. * **B. Cytochrome P450 (CYP3A4) Inhibitors:** Ciclosporin is extensively metabolized by the hepatic CYP3A4 enzyme system. Drugs that inhibit this system (e.g., Erythromycin, Ketoconazole, Diltiazem) decrease Ciclosporin metabolism, leading to toxic blood levels. Conversely, CYP inducers (e.g., Rifampicin, Phenytoin) lower levels, risking graft rejection. * **C. NSAIDs:** Ciclosporin causes vasoconstriction of the afferent arterioles, reducing renal blood flow. NSAIDs inhibit prostaglandins, which are necessary to maintain afferent arteriolar vasodilation. Combining the two leads to synergistic pre-renal vasoconstriction and acute-on-chronic nephrotoxicity. **Clinical Pearls for NEET-PG:** * **Gingival Hyperplasia:** A classic side effect of Ciclosporin (also seen with Phenytoin and Nifedipine). * **Monitoring:** Therapeutic Drug Monitoring (TDM) is essential for Ciclosporin due to its narrow therapeutic index. * **Metabolic Profile:** Ciclosporin is associated with "H" side effects: **H**ypertension, **H**yperlipidemia, **H**yperglycemia, **H**irsutism, and **H**yperkalemia. * **Tacrolimus vs. Ciclosporin:** Tacrolimus is more potent and lacks hirsutism/gingival hyperplasia but has a higher incidence of New-Onset Diabetes After Transplantation (NODAT).

Question 4: What type of graft is a graft from a sister to a brother?

A. Isograft
B. Allograft (Correct Answer)
C. Autograft
D. Heterograft

Explanation: ### Explanation The correct answer is **Allograft (Option B)**. **1. Why Allograft is correct:** An **allograft** (or homograft) is a transplant between two genetically non-identical members of the same species. Since a brother and sister share approximately 50% of their genetic material (unless they are monozygotic twins), they are genetically distinct individuals. Therefore, any organ or tissue transfer between them is classified as an allograft. This requires immunosuppression to prevent T-cell mediated rejection. **2. Why other options are incorrect:** * **Isograft (Option A):** This is a graft between genetically identical individuals. In humans, this only occurs between **monozygotic (identical) twins**. Since the question specifies a brother and sister (who are dizygotic/siblings), they cannot be genetically identical. * **Autograft (Option C):** This involves a graft taken from one part of a patient's body and transferred to another part of the **same individual** (e.g., a skin graft from the thigh to the arm or a CABG using the radial artery). There is no risk of rejection. * **Heterograft (Option D):** Also known as a **Xenograft**, this is a transplant between members of **different species** (e.g., a porcine/pig heart valve transplanted into a human). **3. Clinical Pearls for NEET-PG:** * **Hyperacute Rejection:** Occurs within minutes to hours due to pre-formed antibodies (Type II Hypersensitivity). * **Acute Rejection:** Occurs within days to weeks; primarily T-cell mediated (Type IV Hypersensitivity). * **Chronic Rejection:** Occurs months to years later; characterized by fibrosis and vascular occlusion. * **Order of Immunogenicity:** Xenograft > Allograft > Isograft = Autograft. * **Graft-versus-Host Disease (GVHD):** Most common in bone marrow transplants where donor T-cells attack the recipient's tissues.

Question 5: Compared to early immunosuppressive drugs such as azathioprine, steroids, and anti-lymphocyte serum, what specific advantages do newer immunosuppressive agents offer?

A. Cyclosporine interferes with lymphokine production and has neither bone marrow nor renal toxicity.
B. Monoclonal antibody (OKT3) is more available, more specific, and has fewer side effects than anti-lymphocyte serum.
C. Tacrolimus (FK506) shares properties with cyclosporine but is particularly useful for rescuing grafts failing under cyclosporine therapy. (Correct Answer)
D. None of the above.

Explanation: This question tests your knowledge of the evolution of immunosuppressive therapy in transplant surgery, specifically the transition from non-specific agents to targeted calcineurin inhibitors (CNIs). ### **Explanation of the Correct Option** **Option C** is correct because **Tacrolimus (FK506)** and Cyclosporine are both calcineurin inhibitors that inhibit IL-2 production. However, Tacrolimus is significantly more potent (10–100 times). Clinically, Tacrolimus is the preferred agent for **"rescue therapy"** in patients experiencing refractory acute rejection while on Cyclosporine-based regimens. It has superior efficacy in preventing and treating rejection episodes in kidney and liver transplants. ### **Analysis of Incorrect Options** * **Option A:** While Cyclosporine does interfere with lymphokine (IL-2) production and lacks significant bone marrow toxicity (unlike Azathioprine), it is notoriously **nephrotoxic**. Renal toxicity is its most significant dose-limiting side effect. * **Option B:** While **OKT3** (a murine monoclonal antibody against CD3) is more specific than polyclonal anti-lymphocyte serum (ALS), it is associated with severe side effects, most notably **Cytokine Release Syndrome (CRS)**. Furthermore, OKT3 has largely been phased out in modern practice due to the development of safer monoclonal antibodies like Basiliximab. ### **High-Yield NEET-PG Pearls** * **Mechanism of Action:** Both Tacrolimus and Cyclosporine inhibit **Calcineurin**, preventing the dephosphorylation of **NFAT** (Nuclear Factor of Activated T-cells), which stops IL-2 transcription. * **Binding Proteins:** Cyclosporine binds to **Cyclophilin**; Tacrolimus binds to **FK-binding protein (FKBP-12)**. * **Side Effect Profile:** * **Cyclosporine:** Gingival hyperplasia, hirsutism, and hyperlipidemia. * **Tacrolimus:** Post-transplant diabetes mellitus (PTDM/NODAT) and more significant neurotoxicity (tremors). * **Drug of Choice:** Tacrolimus is currently the mainstay of maintenance immunosuppression in most solid organ transplants.

Question 6: A parathyroid gland is implanted into the forearm muscle. What type of transplantation is this?

A. Orthotopic
B. Heterotopic (Correct Answer)
C. Auxiliary
D. None of the above

Explanation: ### Explanation The correct answer is **Heterotopic** transplantation. **1. Why Heterotopic is Correct:** In transplant surgery, the classification is based on the anatomical site of implantation. **Heterotopic transplantation** occurs when a tissue or organ is implanted into an anatomical location different from its original physiological position. * **Clinical Context:** In patients undergoing total parathyroidectomy (e.g., for secondary hyperparathyroidism), a portion of the parathyroid gland is often autotransplanted into the **brachioradialis muscle** of the forearm. This allows the gland to maintain endocrine function while being easily accessible for monitoring or partial resection if recurrence occurs. **2. Why Other Options are Incorrect:** * **Orthotopic (Option A):** This refers to placing the graft in its **normal anatomical position** after removing the diseased organ. A classic example is a Liver Transplant, where the donor liver replaces the recipient's liver in the right upper quadrant. * **Auxiliary (Option C):** This is a subtype of heterotopic transplant where the graft is placed in a different location **without removing the recipient's native organ**. The graft "assists" the failing organ. An example is an auxiliary liver transplant placed in the infra-mesocolic space. **3. High-Yield Clinical Pearls for NEET-PG:** * **Autograft:** Transfer of tissue within the same individual (e.g., the parathyroid forearm transplant mentioned above). * **Allograft:** Transfer between genetically different members of the same species (most cadaveric organ transplants). * **Isograft (Syngeneic):** Transfer between genetically identical individuals (monozygotic twins). * **Xenograft:** Transfer between different species (e.g., porcine heart valve). * **Renal Transplant:** Most kidney transplants are **Heterotopic** (placed in the iliac fossa), not orthotopic.

Question 7: Which of the following is not a component of the University of Wisconsin solution?

A. Adenosine
B. Glutathione
C. Allopurinol
D. Potassium citrate (Correct Answer)

Explanation: The **University of Wisconsin (UW) solution** is the "gold standard" for cold storage of intra-abdominal organs (liver, pancreas, and kidney). Its primary goal is to minimize cell swelling and prevent oxidative damage during ischemia. ### Why Potassium Citrate is the Correct Answer The UW solution is an **intracellular-type** solution, meaning it contains high concentrations of potassium and low concentrations of sodium to mimic the intracellular environment. However, the potassium source in UW solution is **Potassium Lactobionate**, not Potassium citrate. Potassium citrate is typically used in cardioplegic solutions (like St. Thomas solution) to induce cardiac arrest, but it is not a component of the UW formula. ### Explanation of Incorrect Options * **Adenosine (Option A):** Included as a precursor for ATP synthesis, helping the organ regain energy stores once reperfused. * **Glutathione (Option B):** Acts as a potent antioxidant to reduce oxidative stress and neutralize free radicals during the reperfusion phase. * **Allopurinol (Option C):** A xanthine oxidase inhibitor that prevents the formation of reactive oxygen species (ROS), protecting the graft from reperfusion injury. ### High-Yield Clinical Pearls for NEET-PG * **Key Components of UW Solution:** Lactobionate and Raffinose (prevent osmotic swelling), Hydroxyethyl starch (HES - prevents interstitial edema), and Magnesium sulfate. * **Mechanism:** It works by preventing the "sodium-potassium pump" failure that occurs during cold ischemia. * **Storage Time:** It allows for liver preservation for up to 12–18 hours and kidney preservation for up to 48–72 hours. * **Note:** Because of its high potassium content (120 mEq/L), the solution must be thoroughly flushed out of the organ before anastomosis to prevent **systemic hyperkalemia** and cardiac arrest in the recipient.

Question 8: Which immunosuppressive drug is commonly given after renal transplantation?

A. Cyclophosphamide
B. Corticosteroids (Correct Answer)
C. Interferon
D. All of the above

Explanation: **Explanation:** In renal transplantation, the primary goal of immunosuppression is to prevent graft rejection while minimizing systemic toxicity. **Corticosteroids** (such as Prednisolone) are a cornerstone of post-transplant maintenance therapy. They act by inhibiting the expression of multiple inflammatory cytokines (like IL-1, IL-2, and TNF-alpha) and suppressing T-cell activation. Most transplant protocols utilize a "triple drug regimen" consisting of a Calcineurin Inhibitor (e.g., Tacrolimus), an Antiproliferative agent (e.g., Mycophenolate Mofetil), and **Corticosteroids**. **Analysis of Options:** * **A. Cyclophosphamide:** While an immunosuppressant, it is primarily used in chemotherapy or for specific autoimmune conditions (like Wegener’s granulomatosis). It is rarely used in routine transplant maintenance due to its significant toxicity profile (e.g., hemorrhagic cystitis). * **C. Interferon:** This is an immunomodulator, not an immunosuppressant. In fact, interferons *stimulate* the immune system to fight viruses or tumors and could potentially trigger graft rejection if administered post-transplant. * **D. All of the above:** Incorrect, as only corticosteroids are standard post-transplant therapy among the choices. **High-Yield Clinical Pearls for NEET-PG:** * **Standard Triple Therapy:** Tacrolimus + Mycophenolate Mofetil (MMF) + Prednisolone. * **Drug of Choice for Induction:** Basiliximab (IL-2 receptor antagonist) or Antithymocyte Globulin (ATG). * **Side Effects of Steroids:** Hyperglycemia (Post-Transplant Diabetes Mellitus), osteoporosis, peptic ulcers, and impaired wound healing. * **Tacrolimus vs. Cyclosporine:** Tacrolimus is generally preferred due to a lower incidence of rejection and fewer cosmetic side effects (like gingival hyperplasia or hirsutism).

Question 9: What is the common site for islet cell transplantation in patients with diabetes mellitus?

A. Forearm muscles
B. Pelvis
C. Thigh
D. Injected into the portal vein (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Injected into the portal vein.** In islet cell transplantation, the goal is to deliver insulin-producing beta cells into a highly vascularized environment that allows for rapid engraftment and glucose sensing. The **portal vein** is the preferred site because it allows the islets to lodge in the **liver sinusoids**. This site is physiologically advantageous as it mimics the natural portal circulation, where insulin is secreted directly into the liver—the primary organ for glucose metabolism. The procedure is typically performed via percutaneous transhepatic catheterization under radiologic guidance. **Why other options are incorrect:** * **A. Forearm muscles:** While the forearm is a common site for **parathyroid autotransplantation**, it lacks the specific microenvironment and portal-venous drainage required for optimal islet cell function and metabolic regulation. * **B. Pelvis:** This is the standard anatomical site for **whole-organ kidney or pancreas transplantation** (specifically the iliac fossa), but it is not used for cellular islet infusion. * **C. Thigh:** Similar to the forearm, the intramuscular environment of the thigh does not provide the necessary vascular architecture or physiological feedback loops for islet survival. **Clinical Pearls for NEET-PG:** * **The Edmonton Protocol:** The landmark protocol for islet transplantation involving corticosteroid-free immunosuppression. * **Source:** Islets are isolated from a cadaveric donor pancreas using **Collagenase** digestion. * **Complications:** The most common immediate complication of portal vein infusion is **portal vein thrombosis** or transient elevation of liver enzymes. * **Success Metric:** The primary goal is achieving "insulin independence," though many patients eventually require supplemental insulin over time.

Question 10: What is the most common indication for heart transplant?

A. Dilated cardiomyopathy (Correct Answer)
B. Myocardial Infarction (MI)
C. Hypertrophic cardiomyopathy
D. Tetralogy of Fallot (TOF)

Explanation: **Explanation:** **Correct Answer: A. Dilated cardiomyopathy** Heart transplantation is the definitive treatment for end-stage heart failure that is refractory to medical management. Globally, the most common indication for heart transplantation in adults is **Dilated Cardiomyopathy (DCM)**, followed closely by Ischemic Cardiomyopathy. DCM leads to progressive ventricular enlargement and systolic dysfunction, eventually reaching a point where the heart can no longer maintain adequate cardiac output. **Analysis of Incorrect Options:** * **B. Myocardial Infarction (MI):** While acute MI is a leading cause of death, it is managed with reperfusion (PCI/CABG). It only leads to transplant if it results in chronic, end-stage **Ischemic Cardiomyopathy**. * **C. Hypertrophic cardiomyopathy (HCM):** Although HCM can lead to heart failure or sudden cardiac death, it is a much less frequent indication for transplant compared to the high prevalence of DCM. * **D. Tetralogy of Fallot (TOF):** This is a congenital cyanotic heart disease usually managed with surgical repair (Blalock-Taussig shunt or total correction) in infancy/childhood. Congenital heart diseases are the most common indication in the **pediatric** age group, but not the overall population. **High-Yield Clinical Pearls for NEET-PG:** * **Most common indication (Adults):** Dilated Cardiomyopathy. * **Most common indication (Pediatrics):** Congenital Heart Disease. * **Gold Standard for Diagnosis of Rejection:** Endomyocardial biopsy (usually taken from the right ventricle). * **Denervated Heart:** A transplanted heart lacks autonomic nerve supply; therefore, it does not respond to Atropine, and patients do not experience classic angina (silent ischemia). * **Most common cause of late death:** Cardiac Allograft Vasculopathy (CAV).

Practice by Chapter

Immunology of Transplantation

Practice Questions

Immunosuppression

Practice Questions

Organ Procurement

Practice Questions

Kidney Transplantation

Practice Questions

Liver Transplantation

Practice Questions

Pancreas Transplantation

Practice Questions

Heart Transplantation

Practice Questions

Lung Transplantation

Practice Questions

Small Bowel Transplantation

Practice Questions

Complications of Transplantation

Practice Questions

Transplantation in Special Populations

Practice Questions

Ethical Issues in Transplantation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free